Establishment of an early warning system for hemorrhage risk of preterm neonates caused by cefoperazone and sulbactam based on pharmacokinetics and risk prediction models

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057588

Enrollment

Unknown

Registered

2022-03-15

Start date

2022-03-14

Completion date

Unknown

Last updated

2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The gestational age at birth is less than 37 weeks; 2. The postnatal age on the first day of medication is less than or equal to 28 days or the corrected weekly age [actual age - (40 weeks - gestational age at birth)] <= 4 weeks; 3. Anti-infective treatment with cefoperazone-sulbactam or piperacillin-tazobactam.

Exclusion criteria

Exclusion criteria: 1. Incomplete inspection or recording of the indicators before and after the medication; 2. The duration of treatment with cefoperazone-sulbactam <= 2 days.

Design outcomes

Primary

Measure	Time frame
Trough plasma concentration of cefoperazone-sulbactam;Blood routine;Blood coagulation index;Liver function;Renal function;	—

Countries

China

Contacts

Public ContactLufen Duan

Suzhou Municipal Hospital

duanlufen@126.com+86 18625010502

Outcome results